Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer-Reference-Cited by-同舟云学术

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer

Published:2020-03-06 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bui Kim Tam¹,Willson Melina L²,Goel Shom³⁴,Beith Jane⁵,Goodwin Annabel¹⁶⁷

Affiliation:

1. Concord Repatriation General Hospital; Medical Oncology Department; 1A Hospital Road Concord NSW Australia 2137

2. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450

3. Peter MacCallum Cancer Centre; Melbourne Australia

4. University of Melbourne; Sir Peter MacCallum Department of Oncology; Melbourne Australia

5. Chris O'Brien Lifehouse; Camperdown NSW Australia 2050

6. The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137

7. Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference141 articles.

1. Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial;Adjuvant Breast Cancer Trials Collaborative Group;Journal of the National Cancer Institute,2007

2. Anonymous Phase III randomised study of adjuvant therapy with tamoxifen vs endocrine ablation vs tamoxifen plus endocrine ablation vs neoadjuvant therapy in patients under 50 with operable breast cancer UKCCCR National Register of Cancer Trials 1997

3. The impact on quality of life of adding chemotherapy (CT) or ovarian suppression (OS) to adjuvant tamoxifen (TAM): outcomes from the UK NCRI Adjuvant Breast Cancer (ABC) trial;Brunt;Journal of Clinical Oncology,2004

4. Results from the UK NCRI adjuvant breast cancer (ABC) international trial: polychemotherapy and ovarian ablation in women with early breast cancer prescribed 5 years tamoxifen;Brunt;British Journal of Cancer,2004

5. George WD Phase III randomised study of adjuvant tamoxifen with or without ovarian suppression and/or cyclophosphamide/methotrexate/fluorouracil (CMF) in premenopausal women with operable invasive breast cancer Physician Data Query (PDQ) 1994

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy;Frontiers in Pharmacology;2024-01-24

2. Ovarian Suppression: Early Menopause, Late Effects;Current Oncology Reports;2024-01-02

3. Role of ovarian suppression in adjuvant treatment of breast cancer;Medical alphabet;2023-12-04

4. Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress;Frontiers in Oncology;2023-10-03

5. Targeting sex steroid biosynthesis for breast and prostate cancer therapy;Nature Reviews Cancer;2023-09-08